Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of RELMADA THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001553643.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- RLMD on Nasdaq
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001553643
- Issuer location
- Coral Gables, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RELMADA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Janus Henderson Group Ltd.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
Lead comparable stake: 10%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
10%
Squadron Capital Management LLC
9.9%
BlackRock, Inc.
7%
Venrock Healthcare Capital Partne...
6.2%
Spruce Street Capital LP
5.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
10%
from 13D/G
|
$76,892,206
11,063,862 shares
|
— | 31 Mar 2026 |
| Squadron Capital Management LLC |
13F
13D/G
Company · Squadron Master Fund LP
|
9.9%
from 13D/G
|
$58,983,014
8,474,571 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
7%
|
$50,882,158
7,352,913 shares
|
$0 | 30 Jun 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
6.2%
|
$46,925,802
6,508,433 shares
|
$0 | 02 Jun 2026 |
| Spruce Street Capital LP |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$42,998,208
6,262,114 shares
|
— | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
5.1%
|
$40,630,789
5,505,527 shares
|
$0 | 27 Apr 2026 |
| Ikarian Capital, LLC |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$18,710,978
2,688,359 shares
|
— | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
4.5%
|
$35,152,106
4,763,158 shares
|
+$3,639,506 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,536,155.
Buys
$2,536,155
Insiders: 4
Sells
$0
Insiders: 0
Net
+$2,536,155
Shares: +1,303,641
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,303,641
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 39,165 | 0 | $161,360 | $0 | +$161,360 |
| 9-12 | 1,264,476 | 0 | $2,374,795 | $0 | +$2,374,795 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to RELMADA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Sergio Traversa
Net 12M change
+$2,536,155
Latest report
12 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | $5,356,000 | +$890,895 | +20% | Filing P/S | 12 Dec 2025 |
| Maged Shenouda | Chief Financial Officer | $3,296,000 | +$1,148,060 | +53% | Filing P/S | 12 Dec 2025 |
| Paul Edward Kelly | COO, Director | $1,105,049 | +$198,000 | +22% | Filing P/S | 12 Dec 2025 |
| Chuck Ence | CA and CO | $888,648 | +$299,200 | +51% | Filing P/S | 12 Dec 2025 |
| Cedric O'Gorman | Chief Medical Officer | $32,185 | Filing P/S | 23 May 2023 | ||
| Fabiana Fedeli | Director | Mixed | 12 Dec 2025 | |||
| Charles J. Casamento | Director | Mixed | 12 Dec 2025 | |||
| John Glasspool | Director | Mixed | 12 Dec 2025 | |||
| Eric Thomas Schmidt | Director | Mixed | 25 May 2023 |
Recent insider transactions for RELMADA THERAPEUTICS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sergio Traversa | RLMD | Common Stock | Purchase | 2.16% | $113,300 | $4.12 | 27,500 | 1,300,000 | 15 Dec 2025 | Direct |
| Maged Shenouda | RLMD | Common Stock | Purchase | 1.48% | $48,060 | $4.12 | 11,665 | 800,000 | 15 Dec 2025 | Direct |
| Sergio Traversa | RLMD | Stock Appreciation Rights | Award | 1,198,000 | 1,198,000 | 12 Dec 2025 | Direct | |||
| Maged Shenouda | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Chuck Ence | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Fabiana Fedeli | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| John Glasspool | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| Paul Edward Kelly | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Charles J. Casamento | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| Chuck Ence | RLMD | Common Stock | Purchase | 50.8% | $299,200 | $2.20 | 136,000 | 403,931 | 05 Nov 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 27.2% | $599,500 | $2.20 | 272,500 | 1,272,500 | 05 Nov 2025 | Direct |
| Maged Shenouda | RLMD | Common Stock | Purchase | 173.4% | $1,100,000 | $2.20 | 500,000 | 788,335 | 05 Nov 2025 | Direct |
| Paul Edward Kelly | RLMD | Common Stock | Purchase | 21.8% | $198,000 | $2.20 | 90,000 | 502,295 | 05 Nov 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 5.93% | $41,422 | $0.7400 | 55,976 | 1,000,000 | 28 Aug 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 15.9% | $86,735 | $0.6700 | 129,455 | 944,024 | 27 Aug 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 11% | $49,938 | $0.6200 | 80,545 | 814,569 | 26 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.